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(57) ABSTRACT 
Cyano-substituted anthracene containing polyamines were 
synthesized and shown to be efficient polyamine transporter 
ligands. Moreover, these compounds (3 and 4) had improved 
fluorescence properties over previously known anthryl-
polyamine conjugates, which facilitated their intracellular 
trafficking by confocal microscopy. These cytotoxic fluores-
cent agents may find use as molecular probes which traffic 
into cells via the polyamine transport system and may also be 
viable anticancer drugs which are readily quantified inhuman 
tissues due to their excellent fluorescence properties: (exci-
tation: A 405 nm) and emission ( 420 nm) occurs in the visible 
light range. The ability to excite and emit in the visible range 
provides an advantage to these probes as these wavelengths 
are not toxic to human cells (versus ultraviolet mediated 
excitations, "A.<400 nm) and visible light lasers are less costly 
to purchase and operate than UV laser sources. 
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1 
FLUORESCENT CYTOTOXIC COMPOUNDS 
SPECIFIC FOR THE CELLULAR 
POLYAMINE TRANSPORT SYSTEM 
RELATED APPLICATION 
2 
disclosed fluorescent PAT pro bes to provide the unique ability 
of tracking the drug into the cell by visualizing the fluorescent 
tag. 
After studying polyamine transport processes for many 
years, we discovered and have previously disclosed com-
pounds 1 and 2 as optimal polyamine transporter (PAT) selec-
tive agents (FIG.1). These compounds enter and kill cells via 
their polyamine transport system. The polyamine transport 
This application claims priority from co-pending provi-
sional application Ser. No. 60/166,889 which was filed on 6 
Apr. 2009, and is also a continuation-in-part of application 
Ser. No. 12/113,540 filed on 1 May 2008, both applications 
being incorporated herein by reference in their entirety. 
10 system is a measurable phenomenon but the genes and pro-
teins involved are poorly understood. The instant invention 
couples our earlier discovery of PAT selective agents 1 and 2 
and modifies their structure to now provide compounds 3 and 
4, which are highly fluorescent compounds useful for track-
FIELD OF THE INVENTION 15 ing polyamine uptake processes in mammalian systems (FIG. 
1). 
The present invention relates to the field of mammalian 
cellular physiology and, more particularly, to fluorescent 
molecules that are transported into a cell via the polyamine 
20 
transporter system. 
BACKGROUND OF THE INVENTION 
We have synthesized these fluorescent probes (compounds 
3 and 4) and performed some confocal microscopy with com-
pound 3 to illustrate this technology in action. An important 
improvement over earlier systems is that even though com-
pounds 1 and 2 are fluorescent they require excitation in the 
ultraviolet range (393 nm) and emit in the visible range (410 
nm). This requirement is detrimental to biological studies as 
25 the UV radiation is injurious and can kill the exposed cells. 
Polyamines are organic compounds having at least two 
primary amine groups, for example NH2 . These compounds 
have a role in the metabolism of mammalian cells but their 
exact functions are not well described. It is known that cells 
30 
can synthesize polyamines and that, if cellular synthesis is 
blocked, exogenously supplied polyamines may be imported 
into the cell via the so called polyamine transporter system. 
While it is known that polyamines are synthesized in cells 
through highly-regulated pathways, their actual function has 35 
not been fully elucidated. 
They are known to bind to DNA as cations, and, in struc-
ture, they represent compounds with cations that are found at 
regularly-spaced intervals (unlike, say, Mg++ or Ca++, which 
40 
are isolated point charges). 
When synthesis of cellular polyamines is inhibited, the 
cell's growth is stopped or severely inhibited. Adding exog-
enous polyamines reactivates the growth of these cells. Most 
eukaryotic cells have a polyamine transporter system on their 45 
cell membrane that facilitates the intake of exogenously pro-
vided polyamines. The polyamine transporter (PAT) system 
is highly active in rapidly proliferating cells and is the target 
of some chemotherapeutics currently under development. 
Polyamines are also known to modulate a number of ion 50 
channels, to enhance permeability of the blood-brain barrier 
and to even regulate senescence in plants, thus being consid-
ered plant hormones. Since many cancer cell lines have active 
polyamine transporters, it is possible to target these cells 
using the molecular recognition events involved in polyamine 55 
import. 
New compounds 3 and 4 contain a cyano group which 
extends the compounds' pi system just enough that these 
systems are now excited at 405 nm (blue light) and emit at 420 
nm (in the visible light range). This improvement in their 
photophysical properties coupled with their high selectivity 
in entering cells via the PAT system make these compounds 
valuable new tools for molecular and cell biologists interested 
in tracking polyamine uptake phenomena via fluorescence 
measurements or via confocal microscopy. 
The present disclosure also contemplates that the invention 
includes the compound of Formula 3 used in manufacturing a 
pharmaceutical composition acceptable for administration to 
a patient. Those skilled in the art should recognize that the 
compounds of this invention may be administered to mam-
mals, preferably humans, either alone or in combination with 
pharmaceutically acceptable carriers, excipients or diluents, 
in a pharmaceutical composition, according to standard phar-
maceutical practice. The compounds can be administered by 
any route but are preferably administered parenterally, 
including by intravenous, intramuscular, intraperitoneal, sub-
cutaneous, rectal and also by topical routes of administration. 
The term "composition" is intended to encompass a prod-
uct comprising the disclosed compounds in amounts effective 
for causing the desired effect in the patient, as well as any 
product which results, directly or indirectly, from combina-
tion of the specific ingredients. However, the skilled should 
understand that when a composition according to this inven-
tion is administered to a human subject, the daily dosage of 
active agents will normally be determined by the prescribing 
physician with the dosage generally varying according to the 
age, weight, sex and response of the individual patient, as well 
as the severity of the patient's symptoms. 
SUMMARY OF THE INVENTION 60 The terms pharmaceutical composition, pharmaceutically 
With the foregoing in mind, the present invention advan-
tageously provides novel fluorescent compounds that are rap-
idly internalized by a cell via the polyamine transporter sys-
tem, thus providing easily tracked pro bes for the further study 
of this transport mechanism. Consequently, it may be pos-
sible to attach a therapeutic drug moiety to the presently 
and/or pharmacologically acceptable for administration to a 
patient refer to molecular entities and/or compositions that do 
not produce an adverse, allergic and/or other untoward reac-
tion when administered to a subject, be it animal or human, as 
65 appropriate. As known to the skilled, a pharmaceutically 
acceptable composition or carrier includes any and/or all 
solvents, dispersion media, coatings, antibacterial and/or 
US 8,410,311 Bl 
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antifungal agents, isotonic and/or absorption delaying agents 
and/or the like. The use of such media and/or agents for 
pharmaceutical active substances is well known in the art. 
Except insofar as any conventional media and/or agent is 
incompatible with the active ingredient, its use in the thera-
peutic compositions is contemplated. Supplementary active 
ingredients can also be incorporated into the compositions. 
For administration, preparations should meet sterility, pyro-
genicity, general safety and/or purity standards as required by 10 
FDA Office of Biologics standards. The skilled will find 
additional guidance in preparation of pharmaceutically 
acceptable compositions by consulting United States Phar-
macopeia (USP) or other similar treatises employed in the 
pharmaceutical industry. 15 
20 
4 
FIG. 2 shows a fluorescence microscopy view of PAT inac-
tive CHOMG cells treated with compound 3 (10 µM) after 4 
hours; 
FIG. 3 again shows a fluorescence microscopy view of 
CHO wild type cells treated with compound 3 (10 µM) after 
4 hours: 
FIG. 4 illustrates a synthetic scheme for producing com-
pound 3 (Reaction Scheme 1 ), wherein reagents are a) BuLi, 
DMF, b) Pd(OAc)2/K4 [Fe(CN)6], c) H2~CH2)4N(Boc) 
(CH2 ) 4 NHBoc, NaBH4 , and d) 4 N HCl; 
FIG. 5 depicts a synthetic scheme for producing compound 
4 (Reaction Scheme 2), wherein reagents employed are (a) 
CuBr2/t-BuONO; (b) NaBH4 , then 3M HCl; (c) vinylene 
carbonate, d) KOH/EtOH to give the dial, then Pb(OAc )4 ; ( e) 
Pd(OAc)iK4 [Fe(CN)6]; (f) H2N(CH2 ) 4 N(Boc)(CH2 ) 4 NH-
Boe, NaBH4 , and (g) 4 N HCl; and 
The present disclosure also contemplates a second com-
pound, of Formula 4 and related to the compound of Formula 
3 by both being derivatives of an anthracene compound. This 
second compound is shown below according to Formula 4 
and salts thereof. The compound of Formula 4 has chemical 
and biological properties that parallel those of the compound 
of Formula 3 and may be employed in a likewise manner, as 
described above. 
FIG. 6 shows a line graph depicting the UV-VIS spectra of 
Ant44 (compound 1) and cyanoAnt44 (compound 3) in PBS 
25 buffer, 100 µMat 25° C. 
As used herein, the terms "treat," "treating" or "method of 
treatment" refer to both therapeutic treatment and prophylac-
35 
tic or preventive measures, wherein the object is to prevent or 
slow down (lessen) an undesired physiological change or 
disorder, such as the development or spread of cancer or other 30 
proliferation disorder. For purposes of this invention, benefi-
cial or desired clinical results include, but are not limited to, 
alleviation of symptoms, diminishment of extent of disease, 
stabilized (i.e., not worsening) state of disease, delay or slow-
ing of disease progression, amelioration or palliation of the 
disease state, and remission (whether partial or total), 
whether detectable or undetectable. For example, treatment 
with a compound of the invention may include reduction of 
undesirable cell proliferation, and/or induction of apoptosis 40 
and cytotoxicity. "Treatment" can also mean prolonging sur-
vival as compared to expected survival if not receiving treat-
ment. 
The terms "effective to inhibit" or "growth inhibitory 45 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described below. Any publications, patent applica-
tions, patents, and other references mentioned herein are 
incorporated by reference in their entirety. In case of conflict, 
the present specification, including any definitions, will con-
trol. In addition, the materials, methods and examples given 
are illustrative in nature only and not intended to be limiting. 
Accordingly, this invention may be embodied in many differ-
ent forms and should not be construed as limited to the illus-
trated embodiments set forth herein. Rather, these illustrated 
amount" of the compounds of the invention refer to an amount 
which reduces (i.e., slows to some extent and preferably 
stops) proliferation of a target cell, such as a tumor cell, either 
in vitro or in vivo, irrespective of the mechanism by which 
cell growth is inhibited (e.g., by cytostatic properties, cyto-
toxic properties, etc.). 
50 embodiments are provided so that this disclosure will be 
thorough and complete, and will fully convey the scope of the 
invention to those skilled in the art. Other features and advan-
tages of the invention will be apparent from the following 
detailed description, and from the claims. 
55 U.S. patent application Ser. No. 12/113,540 was filed on 1 BRIEF DESCRIPTION OF THE DRAWINGS 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
FIG. 1 provides the formulas for previously known com-
pounds 1-2, as well as presently disclosed novel compounds 
3-4 according to an embodiment of the present invention; 
May 2008 and application Ser. No. 12/113,970 was filed on 2 
May 2008. These two applications disclosed other polyamine 
compounds related to and having similar biological proper-
60 ties to the presently disclosed compounds 3 and 4. Accord-
ingly, these two patent applications are incorporated herein 
by reference in their entireties. 
In the present disclosure, using Chinese hamster ovary 
(CHO) cells as a test cell line, we have shown that compound 
65 3 is significantly more toxic to wild-type CHO cells than to 
their CHO MG mutant, which is defective in polyamine trans-
port. Since these compounds use the PAT for cellular entry, 
US 8,410,311 Bl 
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they are very toxic to cell lines containing active polyamine 
transporters (e.g., CHO cells) but less so to cell lines with 
defects in this pathway (CHOMG). 
As known to those skilled in the art, the IC50 is the concen-
tration of the drug required to kill 50% of the relative cell 
population. That is, the lower the IC50 , the more potent the 
drug. See Table 1. We employed confocal microscopy to look 
at the cell localization behavior of compound 3 in these two 
cell lines at different time points. 10 
FIG. 2 shows inactive CHOMG cells treated with com-
pound 3 (10 uM), the fluorescence microscopy view being 
taken after the cells had been exposed to the compound for 4 
hrs. Compound 3 is mainly sequestered in intracellular 15 
vesicles at the 4 hr incubation time-point (FIG. 2). The 
CHOMG mutant defect seems to block vesicular escape of 
the probe. Note that the fluorescent probe, compound 3, 
appears as a blue dot (right image) as it remains localized 
within vesicles. The green image (left image) is acquired from 
an actin-binding stain to show the cells' cytoskeletal archi-
tecture surrounding the blue probe 3. 
In FIG. 3 PAT active CHO wild type cells are shown after 
being treated with compound 3 (10 uM) for 4 hrs. In contrast 25 
to CHO MG, shown in FIG. 2, the wild type CHO cells shown 
in FIG. 3 allow compound 3 to escape the vesicle compart-
ments and arrive at the perinuclear compartment after 4 hrs. of 
incubation. This is clearly seen as the 'blue halo' effect. Note 
30 
that the fluorescent drug, compound 3, appears as a blue 
image. The green image is taken with an actin-binding stain to 
show the cells' cytoskeletal architecture. 
The skilled will recognize that the CHOMG/CHO IC50 
ratio is indicative of PAT selectivity. As seen in Table 1, 35 
control compound 5 (a water soluble anthracene derivative 
with the incorrect message to utilize the polyamine trans-
porter, PAT) gave the same IC50 value in both the CHO and 
CHOMG cell lines. i.e. the CHOMG/CHO IC50 ratio=!. 
Therefore, the control compound 5 had no selectivity for 40 
targeting cells with the active PAT. In contrast, the smart 
polyamine probes 1-4 all showed greater toxicity to the CHO 
cell line over its CHO MG mutant (IC50ratios>>1). In addi-
tion, the L1210 cells (murine leukemia cells) were more 
sensitive (lower IC50 values) to the smart probes 1-4 than the 45 
control 5. These cells also gave lower K, values, which is 
indicative of greater binding to the PAT. In contrast the control 
5 gave a significantly higher K, value (32.2 µM). 
Compd (tether) 
l:Ant-4,4 
2: 4,4-Ant-4,4 
3: cyano-Ant-4,4 
6 
TABLE 1 
Biological Evaluation of polyamine 
derivatives in CHO and CHO-MG cells 
3HC1 
1: Fl, r4, z=4; R~H; x~H 
3: Fl, r4, z=4; R~H; x~cN 
2: Fl, y=4, z~4; X~H 
4: Fl, y=4, z~4; X~CN 
H 
x 
3HC1 
N~NH2 
3HC1 
5: Fl, y=4 
CHO- (CHO- L1210 
MG CHO MG/CHO) K, 
ICso ICso IC so value 
inµM inµM Ratiob inµM 
66.7 0.45 148 1.8 
(±4.1) (±0.10) (±0.1) 
>100 0.045 >2222 0.39 
(±0.003) (±0.05) 
48.7 0.96 51 3.8 
(±1.6) (±0.01) (±0.28) 
L1210 
ICso 
value 
inµM 
0.3 
(±0.1) 
0.78 
(±0.07) 
0.31 
(±0.01) 
A comparison of the UV-visible absorbance spectra of the 
Ant44 (compound 1) and cyanoAnt44 (compound 3) deriva-
tives (FIG. 6) shows a shift to longer wavelength (red shift) of 
the absorbance spectrum upon cyanation of the ring. The 
extended pi system is responsible for this shift to 409 nm and 
was part of the design process in constructing the cyano 
4: cyano-4,4-
50 Ant-4,4 
5:Ant-4 
ND 
7.6 
ND 
7.7 
ND ND ND 
32.2 6.3 
derivative. 55 
An important reason for using >400 nm for polyamine 
probe excitation is that one can use a visible light laser, for 
example a blue laser, to excite the compound at 405 nm. In 
contrast, exciting probes of wavelength below 400 nm would 60 
require a very costly UV laser, which are also expensive to 
maintain and to cool during operation. 
In addition, UV excitation has other problems since other 
biofluorophores such as DNA bases, tryptophan, etc., can be 
excited by UV radiation. Accordingly, in order to distinguish 65 
the presently disclosed polyamine probes it was advanta-
geous to be able to use excitation 
(control) (±0.4) (±0.5) (±4.3) (±0.3) 
acells were incubated for 48 h with the respective conjugate, Ant= anthrylmethyl; 
ba measure of PAT selectivity, not determined 
frequencies in the visible light region. We accomplished this 
by making the cyano derivatives which have an absorption 
band near 409 nm in PBS (see FIG. 6). 
Materials and Methods 
Control compounds 1, 2, and 5 were synthesized previ-
ously. REF: (a) "Synthesis and Biological Evaluation ofN1 -
(anthracen-9-ylmethyl)triamines as Molecular Recognition 
Elements forthe Polyamine Transporter," Wang, C.: Delcros, 
J-G.; Biggerstaff, J.; Phanstiel IV, 0. J. Med. Chem. 2003, 46, 
2663-2671; (b) A Comparison of Chloroambucil- and 
Xylene-containing polyamines leads to improved ligands for 
accessing the polyamine transporter. Navneet Kaur, Jean-
US 8,410,311 Bl 
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Guy Delcros, and Otto Phanstiel IV. J. Med. Chem. 2008, 51, 
1393-1401; (c) "N'-Substituent Effects in the Selective Deliv-
ery of Polyamine-Conjugates into Cells Containing Active 
Polyamine Transporters" Gardner, R. A.; Delcros, J-G.; 
Konate, Breitbeil III, F.; Martin, B.; Sigman, M.; Huang, M.; 
Phanstiel IV, 0. J. Med. Chem. 2004, 47, 6055-6069.) 
10-( ( 4-( 4-amino butylamino) buty !amino )methyl )an-
thracene-9-carbonitrile (3): 
The diBOC amine 8 (0.15 mmol) was dissolved in EtOH (3 
mL) and cooled to 0° C. 4N HCI (6 mL) was added dropwise 
at 0° C. The solution was stirred at it overnight. The solution 
was concentrated under reduced pressure to give a yellow 
solid 3 in 96% yield. 1H NMR (300 MHz. D20): ll 8.18 (d, 
2H), 8.00 (d, 2H), 7.73 (m, 4H), 5.06 (s, 2H), 3.25 (t, 2H), 3.06 
(m, 6H), 1.75 (m, SH). d HRMS: theory for C24H30N43HCI: 
375.2543. found 375.2553. Anal. calcd for 
C24H33N4Cl30.2H20: C, 59.13; H, 6.91; N, 11.49. Found: C, 
59.21; H, 7.01; N, 11.54. 
9-Bromo- l 0-anthracenecarboxaldehyde ( 6): 
To the yellow suspension of 9, 10-Dibromoanthracene (2 g, 
5.95 mmol) in THF (20 mL) at -90° C., n-BuLi (2.88 mL, 
7.18 mmol, 2.5 Min hexane) was added dropwise. Orange 
solution was observed after 45 min additional stirring. Anhy-
drous DMF (0.92 mL, 11.9 mmol) was added to the orange 
solution. The reaction mixture was slowly warmed to room 
temp and stirred overnight. The reaction mixture was 
quenched with H20 and extracted with CH2Cl2. The organic 
layer was washed with 10% aq. Na2C03 solution (3x50 mL). 
The CH2Cl2 layer was separated, dried over anhydrous 
Na2S04, filtered and removed in vacuo to give yellow solid. 
The crude product was purified by colunm chromatography 
using 30% CH2Clihexane to give 6 in 68% yield. Rf=0.3 
(30% CH2Cl2/hexane; 1H NMR (CDCl3) d 11.39 (s, lH), 
8.77-8.82 ( d, 2H), 8.55-8.60 ( d, 2H), 7 .56-7 .67 (m, 4H). (Ref. 
de Montigny, Frederic; Argouarch, Gilles; Lapinte, Claude. 
New route to unsymmetrical 9,10-disubstituted ethynylan-
thracene derivatives. Synthesis, 2006, 2, 293-298.) 
9-Cyano- l 0-anthraldehyde (7): 
8 
oil bath at 80° C. and let the reaction stir at 80° C. for three 
hours. After monitoring the consumption of 6 by TLC ( 40% 
CH2CliHexane), EtOAc (20 mL) was added to the reaction 
mixture and crude reaction mixture was washed with satu-
5 rated solution ofK2C03, organic layer was again washed with 
saturated solution ofNH4Cl. The EtOAc layer was dried over 
anhydrous Na2S04, filtered and removed in vacuo to give 
yellow solid 7 in 89% yield by NMR. 
( 4-tert-Butoxycarbonylamino-butyl)-{ 4-[ (10-cyano-an-
lO thracen-9-ylmethyl)-amino ]-butyl}-carbamic acid tert-butyl 
ester (8): 
To a stirred solution ofN1 ,N5 -di-Boe homospermidine (92 
mg, 0.26 mmol) in 25% MeOH/CH2Cl2 (10 mL), was added 
15 a solution of 9-Cyano-10-anthraldehyde 7 (49 mg, 0.21 
mmol) in 25% MeOH/CH2Cl2 (10 mL) under N2. The mix-
ture was stirred at room temperature overnight until the imine 
formation was complete (monitored by NMR). The solvent 
was removed in vacuo, the solid residue dissolved in 50% 
20 MeOH/CH2Cl2 (20 mL) and the solution cooled to 0° C. 
NaCNBH3 (0.25 mmol) was added in small portions to the 
solution and the mixture was stirred at it overnight. The 
solvent was removed in vacuo, the solid residue dissolved in 
CH2Cl2 (30 mL) and washed with Na2C03 solution (10% aq. 
25 3x30 mL). The CH2Cl2 layer was dried over anhydrous 
Na2S04, filtered and removed in vacuo to give an oily residue. 
The oil was purified by flash column chromatography (1.5% 
MeOH/CH2Cl2) to yield the product as a pale yellow solid (93 
mg, 73%), Rf=0.23 (3% MeOH/0.5% NH40H/CH2Cl2); 1H 
30 NMR (300 MHz, CDCl3) ll 8.38 (m, 4H), 7.64 (m, 4H), 4.70 
(s, 2H), 3.12 (m, 6H), 2.89 (m, 2H), 1.41-1.56 (m, 26H): 13C 
NMR: ll 156.0, 155.6, 139.1, 133.1, 129.6, 128.5, 127.0, 
126.2, 125.1, 117.5, 79.4, 53.7, 50.6, 46.9, 46.1, 40.4, 28.7, 
27.7, 26.1. HRMS (FAB)m/zcalcd. forC34H46N40 4 (M+Ht 
35 575.3592. found 575.3591. Anal. calcd for 
C34H46N40 4.1H20: C, 68.89; H, 8.16; N, 9.45. Found: C, 
68.77; H, 8.02; N, 9.42. 
2-Bromoanthraquinone (10): 
Copper (II) bromide (35.0 g, 0.157 mo!, 3.76 equiv.) was 
dissolved in freshly-distilled acetonitrile (200 mL) at room 
temperature to form an opaque dark-green solution. tert-Bu-
tyl nitrite (15 mL, 12.9 g, 0.125 mo!, 1.49 equiv.) was added 
at 0° C. and stirred for 30 minutes at 0° C. 2-Aminoan-
thraquinone 9 (18.60 g, 0.0834 mo!, 1 equiv.) was dissolved in 
9-Bromo- l 0-anthracenecarboxaldehyde (200 mg, 0. 7 40 
mmol) was heated with copper (I) cyanide (75.4 mg, 0.84 
mmol) and pyridine (3 mL) for 12 hr at 230° C. After cooling, 
the mixture was washed with dilute NH40H and ether. The 
ether extract was washed with water, IN HCI, again water, 
dried over anhydrous Na2S04, filtered and removed in vacuo 45 tetrahydrofuran (THF, 300 mL) at room temperature to form 
an opaque red-brown solution. The 2-aminoanthraquinone 9 
solution was quickly added to the copper (II) bromide solu-
tion at 0° C. and the solution was stirred for 2 hours at 0° C. 
to give yellow solid, which was purified using colunm chro-
matography using 40% CH2Cl2/hexane in 40% yield. 1H 
NMR (CDCl3) ll 11.43 (s, lH), 8.72-8.77 (d, 2H), 8.44-8.49 
(d, 2H), 7.71-7.77 (m, 4H); 13C NMR (CDCl3) ll 193.4, 
160.8, 129.9, 129.4, 129.0, 126.3, 124.4. (Ref. Gore, P.H.; 50 
Gupta, S. D.; Obaji, G. A. Anomalous reactions of cyanide 
with two hindered aromatic aldehydes. Journal fuer Prak-
tische Chemie (Leipzig). 1984, 326, 381-4.) 
Optimized Procedure: 
DMAC (N,N-dimethylacetamide) was used as a solvent. 55 
As reaction is oxygen sensitive, DMAC was placed in three 
necked round bottom flask with three way stopcock with 
vacuum line in one side and ultra dry N 2 balloon on the other 
side. Evacuation of the flask was done and DMAC was kept 
under N 2 environment. To three necked flask Bromoaldehyde 60 
6 (25 mg, 0.088 mmol), Zn(CN)2 (18.5 mg, 0.157 mmol), 
Pd2(dba)3 (2.09 mg, 0.002 mmol), Zn dust (1 mg, 0.022 
mmol) were weighed out and flask was evacuated and N 2 was 
allowed to enter the flask via three way stopcock. DMAC ( 4 
mL) was added to the flask via a syringe keeping the flask 65 
under vacuum. t-Butyl phosphine (1.77 mg, 0.009 mmol) was 
added via syringe. The whole assembly was transferred in an 
with venting of the nitrogen gas by-product every 5 minutes 
until the bubbling ceased. The consumption of 2-aminoan-
thraquinone 9 was monitored by thin-layer chromatography 
(100% CHCl3, Rf=0.32). Once the 2-aminoanthraquinone 9 
was consumed, the THF and acetonitrile solvents were 
removed from the mixture via rotary evaporation to give a 
brown and black solid residue. The solid was rinsed with 
deionized water to form a suspension. The resulting slurry 
was vacuum filtered and rinsed with deionized water. The 
filtration receiving flask was changed and the solid was 
washed with CH2Cl2 through the filter paper, leaving a red-
brown solid by-product and forming a yellow-brown solu-
tion. The CH2Cl2 was removed from the solution via rotary 
evaporation, leaving a yellow solid consisting of the product 
2-bromoanthraquinone 10 and by-product anthraquinone. 
The desired product was separated and purified from the 
unwanted by-product through colunm chromatography (35% 
CHCl3/hexane, Rf=0.33 and Rf=0.28 respectively), providing 
2-bromoanthraquinone 10 as a light yellow solid (11.2 g; 
US 8,410,311 Bl 
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37%). 1H NMR (CDCl3 ): ll 8.42 (d, lH), 8.30 (m, 2H), 8.16 
(d, lH), 7.91 (dd, lH), 7.80 (m, 2H). 
2-Bromoanthracene (11 ): 
2-Bromoanthraquinone 10 (8.50 g, 0.0296 mo!, 1 equiv) 
and a 50:50 mixture ofisopropyl alcohol and tetrahydrofuran 5 
(200 mL) were stirred for 10 minutes at 0° C. forming a 
yellow suspension. NaBH4 (6.70 g, 0.177 mo!, 6.0 equiv.) was 
added to the suspension at 0° C. The mixture was stirred at 0° 
C. for three hours, turning red in color. The solution was then 
warmed to room temperature. Additional NaBH4 (3.35 g, 10 
0.089 mo!, 3.0 equiv.) was added to the solution at room 
temperature and the solution was stirred at room temperature 
for 12 hours, turning into an orange suspension. Deionized 
water (10 mL) was added to the solution at room temperature 
and the solution was stirred at room temperature for an addi- 15 
tional 12 hours. The consumption of2-bromoanthraquinone 
10 was monitored by thin-layer chromatography (35% 
CHCl3 /hexane, Rf=0.33). Once the consumption of 2-bro-
moanthraquinone 10 stopped entirely (it was never fully con-
sumed), the volatiles were removed by rotary evaporation. 3 20 
M HCI was slowly added to the solution until bubbling 
ceased, then additional 3 M HCI (30 mL) was added. The 
solution was heated at reflux for 6 hours, turning into an 
opaque, yellow suspension in the process. The mixture was 
cooled to room temperature, turning into a transparent solu- 25 
tion containing yellow-brown crystals. The contents under-
went rotary evaporation as much water as possible. The con-
tents were then vacuum-filtered and washed using deionized 
water to remove any water, acid and ionic salt, leaving behind 
a yellow-brown colored solid. The vacuum-filtration receiv- 30 
ing flask was changed and the solid was washed with CH2Cl2 
through the filter paper. The CH2 Cl2 was removed through 
rotary evaporation. The remaining solid was purified through 
colunm chromatography (100% hexane, Rf=0.27), providing 
2-bromoanthracene 11 as a white, powdery solid (2.00 g, 35 
26%). 1HNMR(CDCl3 ): ll 8.42 (s, lH), 8.34 (s, lH), 8.18 (d, 
lH), 8.01 (m, 2H), 7.87 (d, lH), 7.50 (m, 3H). 
2-Bromo-9, 1O-dihydro-9,1O-ethanoanthracene-11,12-
diol cyclic carbonate (12): 
2-Bromoanthracene 11 (2.05 g, 8.0 mmol, 1 equiv.) and 40 
vinylene carbonate (3.68 mL, 5.00 g, 58 mmol, 7.3 equiv.) 
were heated under reflux with stirring for 18 hours, slowly 
forming a dark brown solution. The consumption of 11 was 
monitored by thin-layer chromatography (2% CH2Cl2/hex-
ane, Rf=0.31). The mixture underwent rotary evaporation 45 
under high vacuum to remove the excess vinylene carbonate, 
providing the cyclic carbonate intermediate 12 as a light-
brown solid (2.74 g, >99%). 1H NMR (CDCl3 ): ll 7.52 (dd, 
lH), 7.37 (m, 3H), 7.27 (m, 3H), 4.88 (m, 2H), 4.66 (m, 2H). 
2-Bromo-9, 1O-dihydro-9,1O-ethanoanthracene-11,12- 50 
dial (12a): 
Solid potassium hydroxide (1.80 g, 32.0 mmol, 4 equiv.), 
deionized water (30 mL ), and absolute ethanol (3 .2 mL) were 
added to the light-brown cyclic carbonate intermediate 12 
(2.74 g, 8.0 mmol, 1 equiv.). The solution was stirredat75° C. 55 
for 3 hours. The consumption of the cyclic carbonate inter-
mediate 12 was monitored through thin-layer chromatogra-
phy (100% CH2 Cl2 , Rf=0.30). Afterwards, the solution 
underwent rotary evaporation under reduced pressure to 
remove the ethanol and roughly half of the water volume. 60 
Additional water (60 mL) was added to the solution and the 
solution was stirred at room temperature for one hour, result-
ing in the formation of light-tan solid. The contents were 
vacuum-filtered and then washed with deionized water. The 
vacuum-filtration receiving flask was changed and the solid 65 
was washed with ethyl acetate through the filter paper. The 
ethyl acetate was removed through rotary evaporation, leav-
10 
ing a white solid residue. The product was purified through 
colunm chromatography (90% CH2 Cl2/ethyl acetate, 
Rf=0.30 & Rf=0.15), providing two isomers of dial interme-
diate 12a as a white solid (2.01 g, 79%). 1HNMR (CDCl3 ): ll 
7.52 (d, lH), 7.35 (dd, lH), 7.31(dd,2H), 7.25 (d, lH), 7.17 
(dd, 2H), 4.40 (dd, 2H), 4.07 (m, 2H). 1H NMR (CDCl3 ): ll 
7.45 (d, lH), 7.34 (dd, 2H), 7.27 (dd, lH), 7.20 (dd, 2H), 7.16 
(d, lH), 4.35 (dd, 2H), 4.05 (d, 2H). 
2-Bromo-9, 10-anthracenedialdehyde (13 ): 
Dial intermediate 12a (1.58 g, 5.0 mmol, 1 equiv.) was 
dissolved in anhydrous acetonitrile (100 mL) and heated to 
reflux with stirring and formed a transparent, light-tan solu-
tion. Lead tetraacetate ( 4.42 g, 10.0 mmol, 2 equiv.) was 
added portion-wise to the solution over a period of 5 minutes 
quickly turning the solution opaque and brown in color. The 
solution was then stirred at reflux for 4 hours, resulting in the 
formation of a dark-orange precipitate within the brown solu-
tion. The consumption of the dial intermediates were moni-
tored through thin-layer chromatography (80% CH2Cliethyl 
acetate, Rf=0.50 & Rf=0.33).Afterthereaction was complete, 
the reaction mixture was concentrated via rotary evaporation 
and gave a burgundy residue. 10% aqueous sodium carbonate 
(300 mL) was added to the residue, allowing the residue to be 
suspended in the aqueous solution. The organic contents were 
extracted from the aqueous layer using dichloromethane. The 
opaque, yellow organic layer was dried over anhydrous 
sodium sulfate, filtered, and concentrated to give a yellow-
orange solid residue. The residue was purified by colunm 
chromatography (20% ethyl acetate/hexane, Rf=0.29), pro-
viding 2-bromo-9, 10-anthracenedialdehyde 13 as an orange 
solid (1.23 g, 80%). 1H NMR (CDCl3 ): 11.43 (s, lH), 11.42 
(s, lH), 9.03 (s, lH), 8.72 (m, 2H), 8.66 (d, lH), 7.75 (m, 3H). 
Advantages of the Present Invention Over Prior Technology. 
The novelty or improvement on the earlier systems is that 
even though compounds 1 and 2 are fluorescent they require 
excitation in the ultraviolet range (393 nm) and emit in the 
visible range ( 410 nm). This requirement is detrimental to 
biological studies as the UV radiation uses expensive UV 
lasers, which are costly to maintain and cocl during operation. 
The new compounds 3 and 4 contain a cyano group which 
extends the compounds' pi system just enough that these 
systems are now excited at 405 nm (blue light) and emit at 420 
nm (in the visible light range). This improvement in their 
photophysical properties coupled with their high selectivity 
in entering cells via the polyamine transport system make 
these valuable new tools for molecular biologist and cell 
biologists interested in tracking polyamine uptake phenom-
ena via fluorescence measurements or via confocal micros-
copy. 
While there are numerous biological stains for tracking or 
labeling cellular organelles, there are no commercial stains or 
fluorescent agents that specifically enter and traffic through 
the cell membrane via the polyamine transport system. The 
novel compounds herein disclosed can be used to study 
polyamine transport processes in living cells and to track 
potential therapeutic agents tagged thereon. Accordingly, 
advantages of the disclosed compounds include their special 
PAT targeting ability and their desirable photophysical prop-
erties. 
These compounds, as cellular stains, are further useful 
added to cancer cells to track how the cancers are trafficking 
their polyamine growth factors. These agents may also serve 
as trackable anticancer drug candidates as they are cell selec-
tive for active PATs and are cytotoxic at µM concentrations. 
As shown in FIGS. 2 and 3, the probes are able to discern 
between PAT-active and PAT-inactive cell lines (blue halo vs 
dots, respectively). 
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Prior to the present disclosure there were no commercial 
stains or fluorescent agents that specifically enter cells and 
traffic through the polyamine transport system. This is likely 
a multi-step process and is likely a time dependent phenom-
enon. We see an initial sequestration of compound 3 into 
vesicles followed by escape to reach the perinuclear compart-
ment. 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-
tion and although specific terms may have been employed, the 10 
terms are used in a descriptive sense only and not for purposes 
of limitation. The invention has been described in consider-
able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
tions and changes can be made within the spirit and scope of 15 
the invention as described in the foregoing specification and 
as defined in the appended claims. 
That which is claimed: 
1. A fluorescent cyano-substituted anthracene polyamine 
compound according to formula 3 20 
Formula 3 
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2. The compound of claim 1 used in manufacturing a phar-
maceutically acceptable composition. 
3. The compound of claim 1 used in a method of treatment 
by being administered to a patient. 
4. The compound of claim 1 used in a method of treatment 
by being administered to a patient in an amount effective to 
inhibit a cancer cell. 
5. A fluorescent derivative of the compound of claim 1, the 
derivative according to formula 4 
Formula4 
H H 
N~~N......_ 
N H. 
H 
CN 
H H 
N~~N......_ 
N H. 
H 
25 6. The compound of claim 5 used in manufacturing a phar-
maceutically acceptable composition. 
CN 
7. The compound of claim 5 used in a method of treatment 
by being administered to a patient. 
8. The compound of claim 5 used in a method of treatment 
30 by being administered to a patient in an amount effective to 
inhibit a cancer cell. 
* * * * * 
